We are live on
!
Find out more
Lazard Asset Management Portfolio holdings
AUM
$60.8B
1-Year Est. Return
22.47%
This Fund
S&P 500
This Quarter
Est. Return
+5.89%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+302.07%
AUM
$47.8B
AUM Growth
+$3.07B
(+6.9%)
Cap. Flow
-$507M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
17.74%
Holding
1,131
New
130
Increased
292
Reduced
306
Closed
143
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$526M |
| 2 |
Ally Financial
ALLY
|
+$198M |
| 3 |
CSX Corp
CSX
|
+$191M |
| 4 |
NetEase
NTES
|
+$173M |
| 5 |
Norwegian Cruise Line
NCLH
|
+$171M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$262M |
| 2 |
CVS Health
CVS
|
+$240M |
| 3 |
Mastercard
MA
|
+$204M |
| 4 |
McKesson
MCK
|
+$201M |
| 5 |
Molson Coors Class B
TAP
|
+$171M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 14.83% |
| 2 | Communication Services | 13.94% |
| 3 | Technology | 12.15% |
| 4 | Financials | 10.5% |
| 5 | Energy | 9.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ABE
201
DELISTED
Aberdeen Emerging Markets Smaller Company Opportunities Fund
ABE
| $32M | 0.07% |
2,222,048
-7,100
| -0.3% | -$98.5K |
|
202
iShares MSCI Japan ETF
EWJ
$21.7B
| $31M | 0.06% |
643,257
-154,400
| -19% | -$7.05M |
|
203
Vanguard FTSE Pacific ETF
VPL
$8.04B
| $30.3M | 0.06% |
486,417
+23,620
| +5% | +$1.42M |
|
204
Everest Group
EG
$15.4B
| $29.9M | 0.06% |
186,595
-2,429
| -1% | -$384K |
|
205
PepsiCo
PEP
$190B
| $29.7M | 0.06% |
332,969
+3,411
| +1% | +$295K |
|
206
Kennametal
KMT
$2.69B
| $29.2M | 0.06% |
631,119
+240,433
| +62% | +$11.1M |
|
207
TRI-Continental Corp
TY
$1.88B
| $29.2M | 0.06% |
1,389,914
-350,362
| -20% | -$7.16M |
|
|
FCE.A
208
DELISTED
Forest City Realty Trust, Inc.
FCE.A
| $28.7M | 0.06% |
1,444,474
| – | – |
|
|
PACW
209
DELISTED
PacWest Bancorp
PACW
| $28.6M | 0.06% |
662,659
+61,674
| +10% | +$2.57M |
|
210
3M
MMM
$90.9B
| $28.3M | 0.06% |
236,162
-43,904
| -16% | -$5.15M |
|
|
HTO
211
H2O America
HTO
$2.67B
| $27.7M | 0.06% |
1,019,001
-517,753
| -34% | -$14.2M |
|
212
Kimberly-Clark
KMB
$37B
| $27.4M | 0.06% |
257,378
+17,595
| +7% | +$1.87M |
|
213
iShares MBS ETF
MBB
$39.1B
| – | – |
0
| – | – |
|
214
Vanguard Short-Term Corporate Bond ETF
VCSH
$44.7B
| – | – |
0
| – | – |
|
215
Liberty All-Star Equity Fund
USA
$1.77B
| $26.5M | 0.06% |
4,411,493
-1,864,633
| -30% | -$10.9M |
|
|
JOF
216
Japan Smaller Capitalization Fund
JOF
$323M
| $26.4M | 0.06% |
2,798,239
-259,761
| -8% | -$2.31M |
|
217
Gabelli Dividend & Income Trust
GDV
$2.61B
| $26.2M | 0.05% |
1,195,820
-580,862
| -33% | -$12.3M |
|
218
Hershey
HSY
$36.2B
| $26M | 0.05% |
267,303
+64,744
| +32% | +$6.35M |
|
219
Blackstone Mortgage Trust
BXMT
$2.84B
| $25.9M | 0.05% |
894,758
+294,412
| +49% | +$8.51M |
|
220
Wheaton Precious Metals
WPM
$50.9B
| $25.7M | 0.05% |
979,560
+54,875
| +6% | +$1.23M |
|
|
TAM
221
DELISTED
TAMINCO CORP COM
TAM
| $25.4M | 0.05% |
1,092,681
-52,864
| -5% | -$1.1M |
|
222
Green Plains
GPRE
$1.16B
| $25.2M | 0.05% |
766,097
| – | – |
|
223
Extra Space Storage
EXR
$31.7B
| $25.1M | 0.05% |
471,512
-15,044
| -3% | -$776K |
|
224
Ziff Davis
ZD
$1.94B
| $24.9M | 0.05% |
563,064
+16,820
| +3% | +$702K |
|
|
WDR
225
DELISTED
Waddell & Reed Financial, Inc.
WDR
| $24.9M | 0.05% |
397,239
+76,472
| +24% | +$4.95M |
|
Similar funds
QCM
Lazard Asset Management's Q2 2014 Portfolio in Review
As of Q2 2014, Lazard Asset Management held 1,131 positions worth $47.8B, up 6.9% from $44.8B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Lazard Asset Management's Q2 2014 filing shows 130 new, 292 increased, 306 reduced and 143 closed positions. Its largest new stake was Ally Financial: 8,153,883 shares worth $195M. The largest sale was Gilead Sciences, an estimated $262M.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 16% a quarter earlier, followed by Communication Services and Technology.
- Lazard Asset Management's largest Q2 2014 buy was Ally Financial: 8,153,883 shares worth $195M.
- Lazard Asset Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $526M increase.
- Lazard Asset Management's biggest Q2 2014 reduction was Gilead Sciences, cutting an estimated $262M.
- Lazard Asset Management fully exited Mastercard in Q2 2014, selling an estimated $204M.
- Lazard Asset Management's ten largest holdings make up 18% of its $47.8B portfolio in Q2 2014.
- Lazard Asset Management opened 130 new positions and closed 143 in Q2 2014.
- Lazard Asset Management's portfolio value rose 6.9% quarter-over-quarter to $47.8B.
Based on Lazard Asset Management's 13F filing for Q2 2014, filed 12 Aug 2014.